International PPB/DICER1 Registry

Neuroblastoma Clinical Trial

Official title: International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)

Status Recruiting

Clinical Trial Summary

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.

Clinical Trial Description

PPB is a rare cancer of the lung presenting in early childhood, mostly commonly from birth to age ~72 months. PPB occurs within the lung or between the lung and the chest wall. There are three primary forms of PPB called Types I, II, and III PPB. PPB is related to an underlying change/mutation in a gene called DICER1 which impacts gene expression and cell growth. DICER1 mutations may also lead to the development of other tumors in children and adults.

The International PPB/DICER1 Registry offers information based on previous data from Registry participants and the medical literature and collaborative efforts with international rare tumor groups.

Retrospective and real-time central pathology review is encouraged. Therapy decisions remain at the discretion of the treating institution.

Children with Type I PPB require surgery and sometimes chemotherapy. Therapy decisions are the responsibility of the treating institution. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for Type I PPB patients. Chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA).

Children with Types II and III PPB, require surgery, chemotherapy and sometimes radiation therapy. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. ;

Related Conditions & MeSH terms

• Ciliary Body Medulloepithelioma
• Cystic Nephroma
• DICER1 Syndrome
• Disease
• Embryonal Rhabdomyosarcoma
• Embryonal Rhabdomyosarcoma of Cervix
• Goiter, Nodular
• Hyperplasia
• Leydig Cell Tumor
• Nasal Chondromesenchymal Hamartoma
• Neuroblastoma
• Neuroectodermal Tumors, Primitive
• Nodular Hyperplasia of Thyroid
• Ovarian Sarcoma
• Pinealoma
• Pineoblastoma
• Pituitary Cancer
• Pituitary Diseases
• Pituitary Neoplasms
• Pleuropulmonary Blastoma
• Renal Sarcoma
• Rhabdomyosarcoma
• Sarcoma
• Sertoli-Leydig Cell Tumor
• Thyroid Carcinoma
• Thyroid Diseases
• Thyroid Neoplasms
• Wilms Tumor

• NCT number: NCT03382158
• Study type: Observational
• Source: Children's Hospitals and Clinics of Minnesota
• Contact: Kris Ann P Schultz, MD
• Phone: 612-813-7121
• Email: krisann.schultz@childrensmn.org
• Status: Recruiting
• Start date: December 6, 2016
• Completion date: December 6, 2035